As part of the inclusion criteria, the men had to be free of a prior PCa diagnosis, have a non-suspicious digital rectal examination and a serum prostate specific antigen level of ≤ 4 ng/mL (50). The gene discussed is KLK3; the disease is posterior cortical atrophy.